Overall, our results showed a molecular sub-cluster of colon cancer cells with low CDX2 and VDR expression was sensitive to chemotherapy, BRAF inhibitors and PI3K-mTOR inhibitors treatment. This evidence concerns the gene BRAF and colonic neoplasm.